Baxter International Inc (BAX) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Baxter International Inc   (NYSE: BAX)

Select the Financial Report: Select the Period:


Description of Baxter International Inc's Business Segments


Baxter International Inc. is a global healthcare company that provides a diverse range of products and services primarily focused on therapies for individuals with complex medical conditions, including those with chronic illnesses. Baxter operates in multiple segments, and each segment is associated with a variety of products and services aimed at addressing a wide range of healthcare needs.

Segments and Offerings

1. Renal Care
Baxter is a major player in the renal care market, providing solutions for patients with chronic kidney disease and those requiring dialysis treatment. The products and services offered include:

- Peritoneal Dialysis (PD): Baxter offers a range of PD solutions, including dialysis machines and consumables that facilitate home therapy, allowing patients to manage their treatment in their own environments.
- Hemodialysis: The company provides a suite of hemodialysis products, including machines and dialyzers, which are used in both acute and chronic settings.
- Renal Pharmaceuticals: Baxter also has a portfolio of pharmaceuticals designed to manage secondary conditions associated with renal failure, like anemia and minerals and bone disorder treatments.

Hospital Products
This segment encompasses products and services that support healthcare providers in hospitals and clinics, focusing on improving patient outcomes. Key offerings include:

- Intravenous (IV) Solutions: Baxter produces a wide array of IV solutions for hydration, electrolyte replenishment, and nutrition.
- IV Administration and Infusion Systems: The company has developed advanced infusion devices that enhance medication delivery, including smart pumps and equipment that improve safety and efficiency in medication administration.
- Surgical Products: Baxter offers products that support various surgical procedures, including hemostatic agents, surgical mesh, and other related surgical offerings.
- Anaesthesia Products: The company provides a line of products that support anesthesia delivery and monitoring, ensuring patient safety during surgical procedures.

BioScience
The BioScience segment focuses on providing therapeutics that are primarily derived from blood plasma or recombinantly produced. Offerings include:

- Hemophilia Products: Baxter is one of the leading providers of factor replacement therapies used to treat hemophilia A and B, featuring various recombinant clotting factors.
- Immunoglobulin Products: These are used to treat immune deficiencies and autoimmune disorders. Baxter offers both intravenous and subcutaneous immunoglobulin therapies.
- Albumin and Clotting Factors: The company manufactures albumin for critical care and various blood-based clotting factors for patients with bleeding disorders.

Advanced Surgery
Under this segment, Baxter supplies products that cater specifically to the needs of surgical professionals and patients. Key offerings include:

- Surgical Sealants and Adhesives: These medical devices are utilized to facilitate wound closure and minimize bleeding during surgeries.
- Tissue Management Products: Baxter provides a range of bio-surgical products that enhance tissue regeneration and healing.
- Interventional Products: This includes devices used in minimally invasive procedures aimed at enhancing surgical precision and patient care.

Medication Delivery
This segment focuses on safety and efficiency in delivering medications across various settings.

- Smart Infusion Pumps: Advanced technologies for medication delivery that enable dose calculation and monitoring.
- Syringe and IV Bag Systems: Baxter develops and distributes a range of drug delivery systems that improve the safety and reliability of medication administration.
- Controlled Substances: The company offers secure medication management systems for controlled substances, ensuring compliance with regulatory standards.

Services
In addition to tangible products, Baxter provides a range of value-added services to enhance the healthcare experience:

- Patient Support Programs: Tailored initiatives that assist patients in navigating treatment options, medication adherence, and managing chronic conditions effectively.
- Training and Education: Baxter offers comprehensive training programs for healthcare professionals to ensure safe and effective use of their products.
- Supply Chain Solutions: The company provides logistics and management services to help healthcare facilities optimize their inventory and distribution of Baxter products.

Conclusion
Baxter International Inc. demonstrates a robust commitment to meeting the complexities of modern healthcare through its comprehensive portfolio spanning renal care, hospital products, biologic therapies, surgical solutions, and medication delivery systems. Through its products and services, the company aims to improve clinical outcomes and enhance the lives of patients worldwide, aligning closely with the evolving needs of the healthcare industry.


Composition of Baxter International Inc Revenues by Segments

 
2022    0.19 % of total Revenue
2023    0.19 % of total Revenue
2024    0.33 % of total Revenue
2025    0.3 % of total Revenue
2026    0.11 % of total Revenue
United States    53.13 % of total Revenue
International    46.87 % of total Revenue
Medical Products Therapies    47.57 % of total Revenue
Healthcare Systems Technologies    26.1 % of total Revenue
Pharmaceuticals    22.99 % of total Revenue
United States Medical Products Therapies    25.58 % of total Revenue
United States Healthcare Systems Technologies    18.99 % of total Revenue
United States Pharmaceuticals    6.66 % of total Revenue
International Medical Products Therapies    21.99 % of total Revenue
International Healthcare Systems Technologies    7.11 % of total Revenue
International Pharmaceuticals    16.33 % of total Revenue
Infusion Therapies Technologies Medical Products Therapies    36.32 % of total Revenue
Infusion Therapies Technologies United States Medical Products Therapies    19.47 % of total Revenue
Infusion Therapies Technologies International Medical Products Therapies    16.85 % of total Revenue
Advanced Surgery Medical Products Therapies    11.26 % of total Revenue
Advanced Surgery United States Medical Products Therapies    6.11 % of total Revenue
Advanced Surgery International Medical Products Therapies    5.15 % of total Revenue
Care Connectivity Solutions Healthcare Systems Technologies    16.11 % of total Revenue
Care Connectivity Solutions United States Healthcare Systems Technologies    11.66 % of total Revenue
Care Connectivity Solutions International Healthcare Systems Technologies    4.44 % of total Revenue
Front Line Care Healthcare Systems Technologies    10 % of total Revenue
Front Line Care United States Healthcare Systems Technologies    7.33 % of total Revenue
Front Line Care International Healthcare Systems Technologies    2.67 % of total Revenue
Injectables Anesthesia Pharmaceuticals    11.14 % of total Revenue
Injectables Anesthesia United States Pharmaceuticals    6.66 % of total Revenue
Injectables Anesthesia International Pharmaceuticals    4.48 % of total Revenue
Drug Compounding Pharmaceuticals    11.85 % of total Revenue
Drug Compounding International Pharmaceuticals    11.85 % of total Revenue
Other    3.33 % of total Revenue
Other United States    1.89 % of total Revenue
Other International    1.44 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
2022 5.00 0.19 %
2023 5.00 0.19 %
2024 9.00 0.33 %
2025 8.00 0.3 %
2026 3.00 0.11 %
United States 1,435.00 53.13 %
International 1,266.00 46.87 %
Medical Products Therapies 1,285.00 47.57 %
Healthcare Systems Technologies 705.00 26.1 %
Pharmaceuticals 621.00 22.99 %
United States Medical Products Therapies 691.00 25.58 %
United States Healthcare Systems Technologies 513.00 18.99 %
United States Pharmaceuticals 180.00 6.66 %
International Medical Products Therapies 594.00 21.99 %
International Healthcare Systems Technologies 192.00 7.11 %
International Pharmaceuticals 441.00 16.33 %
Infusion Therapies Technologies Medical Products Therapies 981.00 36.32 %
Infusion Therapies Technologies United States Medical Products Therapies 526.00 19.47 %
Infusion Therapies Technologies International Medical Products Therapies 455.00 16.85 %
Advanced Surgery Medical Products Therapies 304.00 11.26 %
Advanced Surgery United States Medical Products Therapies 165.00 6.11 %
Advanced Surgery International Medical Products Therapies 139.00 5.15 %
Care Connectivity Solutions Healthcare Systems Technologies 435.00 16.11 %
Care Connectivity Solutions United States Healthcare Systems Technologies 315.00 11.66 %
Care Connectivity Solutions International Healthcare Systems Technologies 120.00 4.44 %
Front Line Care Healthcare Systems Technologies 270.00 10 %
Front Line Care United States Healthcare Systems Technologies 198.00 7.33 %
Front Line Care International Healthcare Systems Technologies 72.00 2.67 %
Injectables Anesthesia Pharmaceuticals 301.00 11.14 %
Injectables Anesthesia United States Pharmaceuticals 180.00 6.66 %
Injectables Anesthesia International Pharmaceuticals 121.00 4.48 %
Drug Compounding Pharmaceuticals 320.00 11.85 %
Drug Compounding International Pharmaceuticals 320.00 11.85 %
Other 90.00 3.33 %
Other United States 51.00 1.89 %
Other International 39.00 1.44 %
Total 2,701.00 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
2022 -16.67 % -
2023 -28.57 % -
2024 -10 % -
2025 -27.27 % -
2026 - -
United States -3.69 % -
International 11.54 % -
Medical Products Therapies 1.82 % -
Healthcare Systems Technologies 0.14 % -
Pharmaceuticals 6.88 % -
United States Medical Products Therapies -5.21 % -
United States Healthcare Systems Technologies -0.97 % -
United States Pharmaceuticals -7.69 % -
International Medical Products Therapies 11.44 % -
International Healthcare Systems Technologies 3.23 % -
International Pharmaceuticals 14.25 % -
Infusion Therapies Technologies Medical Products Therapies -1.31 % -
Infusion Therapies Technologies United States Medical Products Therapies -9.93 % -
Infusion Therapies Technologies International Medical Products Therapies 10.98 % -
Advanced Surgery Medical Products Therapies 13.43 % -
Advanced Surgery United States Medical Products Therapies 13.79 % -
Advanced Surgery International Medical Products Therapies 13.01 % -
Care Connectivity Solutions Healthcare Systems Technologies 1.87 % -
Care Connectivity Solutions United States Healthcare Systems Technologies -0.32 % -
Care Connectivity Solutions International Healthcare Systems Technologies 8.11 % -
Front Line Care Healthcare Systems Technologies -2.53 % -
Front Line Care United States Healthcare Systems Technologies -1.98 % -
Front Line Care International Healthcare Systems Technologies -4 % -
Injectables Anesthesia Pharmaceuticals -10.15 % -
Injectables Anesthesia United States Pharmaceuticals -7.69 % -
Injectables Anesthesia International Pharmaceuticals -13.57 % -
Drug Compounding Pharmaceuticals 30.08 % -
Drug Compounding International Pharmaceuticals 30.08 % -
Other 15.38 % -
Other United States 6.25 % -
Other International 30 % -
Total 2.9 % -75.98 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -15.00 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Baxter International Inc Divisions, Sales by Country

 
United States   United States Segment contribution to total sales 54.45 % of total Revenue
Medical Products Therapies   Medical Products Therapies Segment contribution to total sales 47.13 % of total Revenue
Healthcare Systems Technologies   Healthcare Systems Technologies Segment contribution to total sales 27.31 % of total Revenue
Pharmaceuticals   Pharmaceuticals Segment contribution to total sales 22.17 % of total Revenue
United States Medical Products Therapies   United States Medical Products Therapies Segment contribution to total sales 25.65 % of total Revenue
United States Healthcare Systems Technologies   United States Healthcare Systems Technologies Segment contribution to total sales 19.95 % of total Revenue
United States Pharmaceuticals   United States Pharmaceuticals Segment contribution to total sales 6.66 % of total Revenue
Infusion Therapies Technologies Medical Products Therapies   Infusion Therapies Technologies Medical Products Therapies Segment contribution to total sales 36.47 % of total Revenue
Infusion Therapies Technologies United States Medical Products Therapies   Infusion Therapies Technologies United States Medical Products Therapies Segment contribution to total sales 19.89 % of total Revenue
Advanced Surgery Medical Products Therapies   Advanced Surgery Medical Products Therapies Segment contribution to total sales 10.65 % of total Revenue
Advanced Surgery United States Medical Products Therapies   Advanced Surgery United States Medical Products Therapies Segment contribution to total sales 5.76 % of total Revenue
Care Connectivity Solutions Healthcare Systems Technologies   Care Connectivity Solutions Healthcare Systems Technologies Segment contribution to total sales 17 % of total Revenue
Care Connectivity Solutions United States Healthcare Systems Technologies   Care Connectivity Solutions United States Healthcare Systems Technologies Segment contribution to total sales 12.2 % of total Revenue
Front Line Care Healthcare Systems Technologies   Front Line Care Healthcare Systems Technologies Segment contribution to total sales 10.32 % of total Revenue
Front Line Care United States Healthcare Systems Technologies   Front Line Care United States Healthcare Systems Technologies Segment contribution to total sales 7.75 % of total Revenue
Injectables Anesthesia Pharmaceuticals   Injectables Anesthesia Pharmaceuticals Segment contribution to total sales 12.02 % of total Revenue
Injectables Anesthesia United States Pharmaceuticals   Injectables Anesthesia United States Pharmaceuticals Segment contribution to total sales 6.66 % of total Revenue
Drug Compounding Pharmaceuticals   Drug Compounding Pharmaceuticals Segment contribution to total sales 10.15 % of total Revenue
Other   Other Segment contribution to total sales 3.39 % of total Revenue
Other United States   Other United States Segment contribution to total sales 2.19 % of total Revenue
Rest of world   Rest of world Segment contribution to total sales 33.16 % of total Revenue
Non-US   Non-US Segment contribution to total sales 45.55 % of total Revenue
Non-US Medical Products Therapies   Non-US Medical Products Therapies Segment contribution to total sales 21.48 % of total Revenue
Non-US Healthcare Systems Technologies   Non-US Healthcare Systems Technologies Segment contribution to total sales 7.36 % of total Revenue
Non-US Pharmaceuticals   Non-US Pharmaceuticals Segment contribution to total sales 15.51 % of total Revenue
Infusion Therapies Technologies Non-US Medical Products Therapies   Infusion Therapies Technologies Non-US Medical Products Therapies Segment contribution to total sales 16.59 % of total Revenue
Advanced Surgery Non-US Medical Products Therapies   Advanced Surgery Non-US Medical Products Therapies Segment contribution to total sales 4.89 % of total Revenue
Care Connectivity Solutions Non-US Healthcare Systems Technologies   Care Connectivity Solutions Non-US Healthcare Systems Technologies Segment contribution to total sales 4.79 % of total Revenue
Front Line Care Non-US Healthcare Systems Technologies   Front Line Care Non-US Healthcare Systems Technologies Segment contribution to total sales 2.57 % of total Revenue
Injectables Anesthesia Non-US Pharmaceuticals   Injectables Anesthesia Non-US Pharmaceuticals Segment contribution to total sales 5.36 % of total Revenue
Drug Compounding Non-US Pharmaceuticals   Drug Compounding Non-US Pharmaceuticals Segment contribution to total sales 10.15 % of total Revenue
Other Non-US   Other Non-US Segment contribution to total sales 1.2 % of total Revenue
Emerging markets   Emerging markets Segment contribution to total sales 12.4 % of total Revenue


Twelve months ended 2025
BAX s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
United States 6,122.00 54.45 %
Medical Products Therapies 5,299.00 47.13 %
Healthcare Systems Technologies 3,071.00 27.31 %
Pharmaceuticals 2,493.00 22.17 %
United States Medical Products Therapies 2,884.00 25.65 %
United States Healthcare Systems Technologies 2,243.00 19.95 %
United States Pharmaceuticals 749.00 6.66 %
Infusion Therapies Technologies Medical Products Therapies 4,101.00 36.47 %
Infusion Therapies Technologies United States Medical Products Therapies 2,236.00 19.89 %
Advanced Surgery Medical Products Therapies 1,198.00 10.65 %
Advanced Surgery United States Medical Products Therapies 648.00 5.76 %
Care Connectivity Solutions Healthcare Systems Technologies 1,911.00 17 %
Care Connectivity Solutions United States Healthcare Systems Technologies 1,372.00 12.2 %
Front Line Care Healthcare Systems Technologies 1,160.00 10.32 %
Front Line Care United States Healthcare Systems Technologies 871.00 7.75 %
Injectables Anesthesia Pharmaceuticals 1,352.00 12.02 %
Injectables Anesthesia United States Pharmaceuticals 749.00 6.66 %
Drug Compounding Pharmaceuticals 1,141.00 10.15 %
Other 381.00 3.39 %
Other United States 246.00 2.19 %
Total 11,244.00 100 %
Rest of world 3,728.00 33.16 %
Non-US 5,122.00 45.55 %
Non-US Medical Products Therapies 2,415.00 21.48 %
Non-US Healthcare Systems Technologies 828.00 7.36 %
Non-US Pharmaceuticals 1,744.00 15.51 %
Infusion Therapies Technologies Non-US Medical Products Therapies 1,865.00 16.59 %
Advanced Surgery Non-US Medical Products Therapies 550.00 4.89 %
Care Connectivity Solutions Non-US Healthcare Systems Technologies 539.00 4.79 %
Front Line Care Non-US Healthcare Systems Technologies 289.00 2.57 %
Injectables Anesthesia Non-US Pharmaceuticals 603.00 5.36 %
Drug Compounding Non-US Pharmaceuticals 1,141.00 10.15 %
Other Non-US 135.00 1.2 %
Emerging markets 1,394.00 12.4 %


Twelve months ended 2025
BAX s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -957.00 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
United States 4.65 % -
Medical Products Therapies 1.77 % -
Healthcare Systems Technologies 4.07 % -
Pharmaceuticals 3.4 % -
United States Medical Products Therapies 0.07 % -
United States Healthcare Systems Technologies 4.13 % -
United States Pharmaceuticals -3.97 % -
Infusion Therapies Technologies Medical Products Therapies -0.05 % -
Infusion Therapies Technologies United States Medical Products Therapies -1.89 % -
Advanced Surgery Medical Products Therapies 8.51 % -
Advanced Surgery United States Medical Products Therapies 7.46 % -
Care Connectivity Solutions Healthcare Systems Technologies 5.35 % -
Care Connectivity Solutions United States Healthcare Systems Technologies 4.65 % -
Front Line Care Healthcare Systems Technologies 2.02 % -
Front Line Care United States Healthcare Systems Technologies 3.32 % -
Injectables Anesthesia Pharmaceuticals -1.53 % -
Injectables Anesthesia United States Pharmaceuticals -3.97 % -
Drug Compounding Pharmaceuticals 9.92 % -
Other 468.66 % -
Other United States 623.53 % -
Total 5.72 % -
Rest of world 8.5 % -
Non-US 7.02 % -
Non-US Medical Products Therapies 3.87 % -
Non-US Healthcare Systems Technologies 3.89 % -
Non-US Pharmaceuticals 6.93 % -
Infusion Therapies Technologies Non-US Medical Products Therapies 2.25 % -
Advanced Surgery Non-US Medical Products Therapies 9.78 % -
Care Connectivity Solutions Non-US Healthcare Systems Technologies 7.16 % -
Front Line Care Non-US Healthcare Systems Technologies -1.7 % -
Injectables Anesthesia Non-US Pharmaceuticals 1.69 % -
Drug Compounding Non-US Pharmaceuticals 9.92 % -
Other Non-US 309.09 % -
Emerging markets 3.26 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.